Back to top
more

Genmab (GNMSF)

(Delayed Data from OTC)

$290.34 USD

290.34
172

-0.10 (-0.03%)

Updated Apr 23, 2024 11:23 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 31% (77 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Why Earnings Season Could Be Great for Genmab (GNMSF)

by Zacks Equity Research

Genmab (GNMSF) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Global Blood (GBT) Reports Narrower-Than-Expected Loss in Q1

by Zacks Equity Research

Global Blood (GBT) reports narrower-than-expected loss in the first quarter of 2019.

Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.

Horizon Therapeutics' (HZNP) Q1 Earnings Beat Estimates

by Zacks Equity Research

Horizon Therapeutics' (HZNP) sales beat estimates in the first quarter of 2019, primarily owing to strong performance of Krystexxa, Ravicti, Procysbi and Rayos.

Amicus' (FOLD) Earnings & Revenues Miss Estimates in Q1

by Zacks Equity Research

Amicus (FOLD) reports wider-than-expected loss in the first quarter of 2019. Also, sales miss estimates.

AMAG Q1 Loss Wider Than Expected, Revenues Lag Estimates

by Zacks Equity Research

AMAG (AMAG) reports wider-than-expected loss and misses sales estimates in the first quarter of 2019.

    What's in the Cards for AcelRx (ACRX) This Earnings Season?

    by Zacks Equity Research

    We expect AcelRx (ACRX) to provide update on the launch of its newly approved drug DSUVIA, when it reports first-quarter 2019 results.

    What's in Cards for Cumberland (CPIX) This Earnings Season?

    by Zacks Equity Research

    Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

    What's in the Cards for Corbus (CRBP) This Earnings Season?

    by Zacks Equity Research

    Corbus (CRBP) will provide updates on its lead candidate lenabasum, when it releases first-quarter 2019 results.

    Seattle Genetics' Adcetris Progresses Well Amid Competition

    by Zacks Equity Research

    Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

    Seattle Genetics Closes Enrollment in Cervical Cancer Study

    by Zacks Equity Research

    Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.

    Seattle Genetics, Astellas Report Positive Cancer Study Data

    by Zacks Equity Research

    Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.

    Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids

    by Zacks Equity Research

    Vertex (VRTX) gains an EU approval for Orkambi to treat 2-5-year-old children suffering cystic fibrosis (CF).

    Genmab (GNMSF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

    by Zacks Equity Research

    Genmab (GNMSF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

    Dr. Reddy's (RDY) Earnings and Revenues Improve Y/Y in Q2

    by Zacks Equity Research

    Dr. Reddy's (RDY) surpasses earnings and revenue estimates on strength across segments in the second quarter of fiscal 2019.

    BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates

    by Zacks Equity Research

    BioMarin's (BMRN) Q3 scores on earnings and revenue beat with a surge in demand for its key products.

    Seattle Genetics (SGEN) Q3 Loss In Line, Sales Top Mark

    by Zacks Equity Research

    Seattle Genetics' (SGEN) loss matches estimates but rides high on revenue beat in Q3.

    Vertex (VRTX) Q3 Earnings and Revenues Surpass Estimates

    by Zacks Equity Research

    Vertex' (VRTX) Q3 gains on earnings and revenue beat with demand for its CF products rising high.

    Emergent Completes Acquisition of Narcan Maker Adapt Pharma

    by Zacks Equity Research

    Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.

      AcelRx's Dsuvia Gets FDA Committee Approval, Shares Rally

      by Zacks Equity Research

      AcelRx (ACRX) earns majority votes from an FDA advisory committee, which recommends approval of Dsuvia for treating moderate-to-severe acute pain in adult patients.

      4 Biotech Stocks with Bright Prospects in 2017

      by Zacks Equity Research

      Even as the drug pricing issue continues to plague the biotech sector, investors should find it safe to bet on these top-ranked biotech stocks that also have superb Style Score as markets roll into 2017.

        5 Top Performing Biotechnology Stocks of November

        by Zacks Equity Research

        November was a great month for pharma/biotech stocks after a rather difficult year when the industry struggled with media and political focus on high drug prices.

          The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte

          by Zacks Equity Research

          The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte